Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
American Journal of Respiratory Cell and Molecular Biology|November 20, 2001
Bleomycin upregulates gene expression of angiotensin-converting enzyme via mitogen-activated protein kinase and early growth response 1 transcription factorR M Day, Y Yang, Y J Suzuki, et al.Cutis|September 1, 1988
Naftifine cream in the treatment of cutaneous candidiasisN Zaias, E Astorga, C N Cordero, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 22, 2016
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)K Reich, M Gooderham, L Green, et al.Biochemistry|February 23, 1999
Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptorW J LaRochelle, K Sakaguchi, N Atabey, et al.Journal of the Royal Society, Interface|June 15, 2012
Rapid magnetic cell delivery for large tubular bioengineered constructsJ Gonzalez-Molina, J Riegler, P Southern, et al.Proceedings of the National Academy of Sciences of the United States of America|September 14, 2000
Unusual 1H NMR chemical shifts support (His) C(epsilon) 1...O==C H-bond: proposal for reaction-driven ring flip mechanism in serine protease catalysisE L Ash, J L Sudmeier, R M Day, et al.Journal of the American Academy of Dermatology|January 1, 1988
Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporisL E Millikan, W K Galen, G B Gewirtzman, et al.The Journal of Biological Chemistry|July 4, 2001
Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signalingJ S Rubin, R M Day, D Breckenridge, et al.The British Journal of Dermatology|September 12, 2015
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)C Paul, J Cather, M Gooderham, et al.Archives of Dermatology|June 2, 1998
Consensus workshop on the toxic effects of long-term PUVA therapyW L Morison, R D Baughman, R M Day, et al.Pageof 5